FDA panel nudges peptide rules closer to clinics despite scientific uncertainty

An FDA advisory panel narrowly voted to loosen restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-c), recommending they be added to the list of compounds that compounding pharmacies may produce, even as agency scientists warned about a lack of evidence and unclear chemical identities; the final decision will come from an FDA rule proposal, with votes showing notable dissent and ongoing safety and data concerns.